Heterogeneity of EGFR mutations in non-small cell lung cancer
10.3760/cma.j.issn.1006-9801.2012.09.001
- VernacularTitle:非小细胞肺癌表皮生长因子受体基因突变的异质性
- Author:
Longhua GUO
;
Yilong WU
;
Qing ZHOU
- Publication Type:Journal Article
- Keywords:
Carcinoma,non-small cell lung;
Receptor,epidermal growm factor;
Mutation;
Hterogeneity
- From:
Cancer Research and Clinic
2012;24(9):577-579,588
- CountryChina
- Language:Chinese
-
Abstract:
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) have shown great efficacy in the treatment of non-small cell lung cancer (NSCLC) patients with EGFR-mutation positive tumors.However,the response to EGFR-TKI is quite different even in EGFR-mutation positive patients.Besides that,different lesions in same patient can also show different response to EGFR-TKI.These phenomena might be associated with the heterogeneity of EGFR mutations,which involves intratumoral heterogeneity,intertumoral heterogeneity,and the heterogeneity before and after treatment.The article introduces the advance in heterogeneity of EGFR mutations from these three aspects.
